AI-Powered Coronary Tool Prompts Medtronic to Acquire Israeli Startup
Medtronic acquires Israeli AI startup CathWorks for up to $585M, enhancing its cardiology portfolio with AI-powered coronary artery disease diagnostics.
Jerusalem, 3 February, 2026 (TPS-IL) — Medtronic, the Ireland-based global healthcare technology leader, announced plans to acquire Israeli medical device company CathWorks, following a 2022 strategic partnership. The deal, valued at up to $585 million, aims to expand Medtronic’s interventional cardiology portfolio and advance how coronary artery disease is diagnosed and treated.
CathWorks, known for its AI-powered FFRangio System, provides comprehensive coronary physiology assessments from routine angiograms, reducing reliance on invasive pressure wires. “Bringing Medtronic and CathWorks together will create a best-in-class organization focused on driving new standards of care,” said CathWorks CEO Ramin Mousavi.
The deal awaits U.S. Federal Trade Commission approval.
